Insitro
Documentation Provided
Overview
Insitro is an artificial intelligence (AI) driven drug discovery and development company that integrates machine learning with high-throughput biology and patient data. Its primary function is to accelerate the identification of disease targets and the design of new therapeutic molecules.
- What it does: Insitro leverages its “Virtual Human” platform, an AI engine built on human clinical and cellular data, to understand disease progression and identify causal disease targets. It also utilizes “TherML” (Therapeutic Machine Learning), a modality-agnostic AI engine for designing small molecules, oligonucleotides, and complex biologics. This platform aims to optimize for both potency and manufacturability simultaneously.
- Who it is for: Insitro’s tools are designed for pharmaceutical companies and researchers involved in early-stage drug discovery and development. Their work spans various therapeutic areas, including metabolic diseases, neuroscience (e.g., ALS), and ophthalmology (e.g., dry AMD).
- How it fits a clinical or practice workflow: Insitro’s technology fits into the preclinical phase of drug development by aiming to identify novel targets and design therapeutic candidates with a higher probability of success. It seeks to streamline the process of translating biological insights into potential treatments by integrating data generation, AI-driven design, and experimental validation.
- Notable capabilities: Key capabilities include the integration of 20+ petabytes of automated cellular experiments with population-scale genetics, the use of causal AI to understand disease mechanisms, and a closed-loop active learning system in TherML that iteratively refines therapeutic design. Insitro has also partnered with organizations like Genomics England to enhance medical data searches using AI.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Causal AI for human health
- Physical AI systems
- Virtual Humanu2122 platform (genetically anchored, causal AI engine)
- TherMLu2122 (modality-agnostic therapeutics design engine)
- Automated cellular experiments
- Population-scale genetics
- Identification of causal disease targets
- Predictive, adaptive drug engineering
Use Cases
- Identifying causal drivers of human disease
- Targeting therapeutics development
- Drug discovery and optimization
- Understanding disease initiation and progression
- Designing small molecules, oligonucleotides, and complex biologics
What Physicians Need to Know
Molecule Screening Capability
Insitro utilizes its TherMLu2122 platform, an AI-driven therapeutics design engine, for modality-agnostic molecule screening, encompassing small molecules, oligonucleotides, and complex biologics. This platform shifts drug discovery from stochastic screening to predictive, adaptive engineering, optimizing for both potency and developability in silico. They also employ proprietary Quantitative Adaptive Libraries (QALs) to generate millions of drug-target binding and selectivity data to inform machine learning models. Their iNDEL platform, a DNA-encoded library (DEL) platform, is a key part of their small molecule strategy, enabling ML-based virtual screening and guiding drug design during hit-to-lead optimization.
Clinical Trial Matching
While Insitro's primary focus is on early drug discovery, their approach to clinical development involves deploying AI models to run smaller, better-powered trials, enrolling patients who can benefit most. This suggests an underlying capability or strategy for patient stratification relevant to clinical trials, though direct 'clinical trial matching' as a standalone feature isn't explicitly detailed.
Real-World Evidence Analysis
Insitro integrates multimodal human cohort data and clinical outcomes with their AI platform. They leverage large-scale clinical and phenotypic data to fuel machine learning models for drug discovery. Their collaboration with Genomics England involves deploying machine learning on multimodal phenotypic and genetic databases, including histopathology images, to derive insights beyond traditional diagnostic labels.
Genomic Data Integration
Insitro's platform is built on combining automated cellular experiments with population-scale genetics to identify causal drivers of human disease. They integrate multimodal human cohort data, genetics, and high-content cellular data. Their 'Virtual Humanu2122' platform is a genetically anchored, causal AI engine that reveals disease progression and identifies causal disease targets. They also collaborate with Genomics England to utilize their extensive genetic and phenotypic database.
Literature Mining
While not explicitly detailed as 'literature mining,' Insitro's approach involves integrating insights through 'Agentic Reasoning' which includes reasoning models and agentic orchestration, suggesting a capability to process and integrate diverse information sources, which could encompass scientific literature.
Target Identification
Insitro's 'Virtual Humanu2122' platform is central to target identification, using a genetically anchored causal AI engine to uncover how diseases begin, progress, and can be resolved, precisely identifying causal disease targets. They apply machine learning and generative AI to build phenotypic disease models and identify genetically supported targets. They have successfully identified novel targets for diseases like ALS in collaboration with Bristol Myers Squibb.
Safety Signal Detection
Insitro develops advanced machine learning models to predict key pharmacological properties of small molecules, including Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties. This capability, developed in collaboration with Eli Lilly and Company, aims to accelerate the design of compounds with favorable ADMET/pharmacokinetic profiles, thereby reducing the risk of late-stage failure and improving safety.
Collaboration Features
Insitro actively engages in strategic partnerships, which are a core part of its strategy. They have significant collaborations with major pharmaceutical companies like Bristol Myers Squibb for neurodegenerative diseases (ALS and FTD) and Eli Lilly and Company for metabolic diseases and small molecule drug discovery. Their platform is designed to allow life scientists, data scientists, engineers, and drug hunters to work together.
Publication Support
Insitro regularly publishes its research and findings in scientific journals and presents at conferences. Their website features a 'Publications & Press' section, highlighting their commitment to sharing scientific progress.
Physician Tip
Insitro's AI-driven platforms, particularly Virtual Humanu2122 and TherMLu2122, offer the potential for identifying novel, genetically supported drug targets and designing therapeutics with optimized properties from the outset. Physicians should be aware that this technology aims to accelerate the discovery of disease-modifying therapies, especially in complex areas like metabolic and neurodegenerative diseases. The focus on causal biology and predictive modeling may lead to more targeted and effective treatments with potentially improved safety profiles, ultimately benefiting patient outcomes. The ability to predict ADMET properties early in drug discovery could translate to fewer adverse events in clinical trials and, eventually, in patient care.
Insitro's platform is built for integration, combining high-throughput biology, machine learning, and diverse datasets. They actively collaborate with pharmaceutical companies, leveraging external data and expertise (e.g., Lilly's extensive drug discovery data for ADMET modeling). The company's embedding search engine is also made available to research partners within the Genomics England Research Environment, demonstrating a capability for data sharing and collaborative analysis within secure environments. This indicates a design philosophy that supports integration with various data sources and research ecosystems.
Details
| Category | Drug Discovery & Research, Lab & Diagnostics |
| Pricing |
Unknown
|
| Languages | English |
| Training | Unknown |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Unknown AI-estimated Insitro is focused on drug discovery and development, aiming to accelerate the process and bring better drugs to patients faster. Their therapeutic candidates are advancing towards First-in-Human studies. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology |
Social Proof
| Customers | unknown |
| Notable | Not specified on websitelikely through partnerships |
Support & Reliability
| Training Provided | Unknown |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Insitro
Press & Coverage
insitro
insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions
insitro presented new data at the American Diabetes Association 86th Scientific Sessions, showcasing its AI-discovered MASH candidate's anti-fibrotic signal, which extends beyond liver-fat reduction.
2026-06
insitro
insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
insitro and Bristol Myers Squibb have expanded their collaboration to include two additional therapeutic targets for ALS, identified through insitro's AI-driven Virtual Humanu2122 platform.
2026-03
insitro
insitro Appoints Joe Hand as Chief People Officer to Advance Talent Strategy for Next Stage of Development
insitro announced the appointment of Joe Hand as Chief People Officer, a move aimed at advancing the company's talent strategy as it enters its next phase of development.
2026-02
insitro
insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects
insitro reported on its first AI-enabled human genetics study of brown adipose tissue, revealing differentiated targets with anti-obesity effects.
2026-02
insitro
insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design
insitro announced its acquisition of CombinAbleAI and the launch of its TherMLu2122 platform, aiming to create a comprehensive, modality-agnostic AI platform for drug discovery and design.
2026-01
insitro
insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery
insitro announced the validation of its AI-enabled POSH platform in Nature Communications, highlighting its role in bridging a critical gap in drug discovery.
2025-12
insitro
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform
insitro and Bristol Myers Squibb extended their research collaboration, focusing on leveraging insitro's ChemML Discovery Platform to find new treatments for ALS.
2025-10
insitro
insitro partners with Lilly to build first-in-kind machine learning models to advance small molecule drug discovery
insitro announced a new collaboration with Eli Lilly and Company to develop advanced machine learning models for predicting pharmacological properties of small molecules, aiming to accelerate drug discovery.
2025-09
Videos
Product demos, reviews, and walkthroughs for Insitro.
Exploring Al Innovation: insitro CEO Daphne Koller on Al in Drug Discovery
Stanford Medicine
AI Native 2025 Fireside Chat | insitro CEO and Founder, Daphne Koller
Zetta Venture Partners
insitro Founder and CEO Daphne Koller at Semafor Tech: First Principles
Semafor Events
Insitro CEO on AI in medicine: Computers find patterns people never would
CNBC Television
Machine learning for drug discovery with insitro's Daphne Koller
Weights & Biases
Whatu2019s next for data-driven medicine - and what AI-powered innovation needs now: insitro CEO Daph...
World Economic Forum
Frequently Asked Questions
Insitro leverages machine learning and high-throughput biology to transform drug discovery. Unlike traditional methods that often involve extensive trial and error, Insitro uses AI to build predictive models from large datasets of biological and patient data, aiming to identify promising drug candidates more efficiently and with a higher probability of success.
Insitro focuses on diseases where AI and scaled data can make a significant impact. While they have partnerships in areas like nonalcoholic steatohepatitis (NASH) with Gilead and have identified targets for ALS with Bristol Myers Squibb, their platform is designed to be modality-agnostic, spanning small molecules, oligonucleotides, and biologics across various therapeutic areas.
Insitro's platform aims to significantly reduce the time and cost associated with drug discovery and development. Industry experts suggest that such AI platforms could decrease preclinical R&D costs by 20-40% and increase the success rate of drug candidates reaching the market, ultimately leading to faster and more affordable drug development.
Despite its potential, Insitro faces challenges such as the high requirement for comprehensive and high-quality datasets to train effective machine learning models. The lack of industry-wide data standards and the need to generate vast amounts of proprietary data in-house can also be limiting factors.
The pharmaceutical industry is highly regulated, and Insitro must blend innovation with strict FDA compliance, ensuring all research, development, and manufacturing processes are auditable. They emphasize rigorous data collection and model validation to build confidence in their AI's predictions, and their collaborations with major pharmaceutical companies like Eli Lilly involve training models on extensive, high-quality proprietary data.
Yes, Insitro operates within a competitive landscape of AI-driven drug discovery companies. Some notable competitors include Zephyr AI, Pepper Bio, and Aitia, all vying for prominence in the market by leveraging technology and biology to advance therapeutic solutions.
Insitro's 'Virtual Human' platform models causal biology at the cellular level by integrating rich biological data and AI. This allows them to understand the underlying causes of disease and identify high-confidence targets before extensive experimental work, leading to more effective medicine discovery.
Suggest an Edit →
| Last Verified: 2026-08-31 | First Added: 2026-08-30
Investors who backed Insitro
Funded through the company that built this tool.
Vijay Pande
Solo Angel
AI
T3
AI/ML in Healthcare
Biotech
David Krane
Solo Angel
AI
T3
AI/ML in Healthcare
Health IT / Healthcare Software
Digitalis Ventures
T1
DVC
VC
T3
AI/ML in Healthcare
Biotech
Third Rock Ventures
VC
T1
AI/ML in Healthcare
Biotech
Two Sigma Ventures
VC
T1
AI/ML in Healthcare
Biotech